Digital rendering of BeiGene's manufacturing site in Hopewell, NJ (Credit: BeiGene)

BeiGene looks be­yond Chi­na as it se­cures new API source, nears open­ing of US site

With many bio­phar­ma com­pa­nies au­dit­ing their man­u­fac­tur­ing sup­ply chains, BeiGene will soon ac­ti­vate a sec­ond API sup­pli­er out­side of Chi­na and will al­so of­fi­cial­ly open its $800 mil­lion bi­o­log­ics pro­duc­tion fa­cil­i­ty in the US in Ju­ly.

“We are near­ing com­ple­tion of full qual­i­fi­ca­tion for a sec­ond API sup­pli­er that will soon be ac­tive. We are con­fi­dent with our cur­rent sup­ply of API and are well po­si­tioned for the fu­ture,” a BeiGene spokesper­son told End­points News, but de­clined to com­ment on time­lines.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.